华北制药2005年半年度报告（节录）_医药资讯

财务资料1、主要会计数据及财务指标单位:元 币种:人民币主要会计数据本报告期末上年度期末本报告期末比上年度期末增减（％）调整后调整前流动资产4,046,265,492.704,029,321,593.794,029,321,593.790.42流动负债5,123,394,436.905,146,361,902.945,146,361,902.94-0.45总资产7,580,911,063.447,611,585,978.727,611,585,978.72-0.40股东权益（不含少数股东权益）1,512,522,834.371,518,961,186.131,518,961,186.13-0.42每股净资产1.991.991.990.00调整后的每股净资产1.201.331.33-9.77报告期（1－6月）上年同期本报告期比上年同期增减（％）调整后调整前净利润2,851,794.5236,125,961.1636,125,961.16-92.11扣除非经常性损益后的净利润3,089,616.4035,561,277.0535,561,277.05-91.31每股收益0.00370.030.03-87.67净资产收益率（%）0.191.441.44减少1.25个百分点经营活动产生的现金流量净额87,432,711.8994,064,253.1294,064,253.12-7.052、扣除非经常性损益项目和金额单位:元 币种:人民币非经常性损益项目金额交易价格显失公允的交易产生的损益0.00处置除公司产品外的其他资产产生的损益90,861.29越权审批或无正式批准文件的税收返还、减免0.00各种形式的政府补贴753,993.00债务重组损益0.00资产置换损益0.00支付或收取并计入当期损益的资金占用费126,000.00短期投资收益0.00委托投资损益0.00扣除资产减值准备后的其他各项营业外收入、支出-1,208,676.17因偶发原因，如因遭受自然灾害而计提的各项资产减值准备0.00以前年度已经计提各项减值准备的转回0.00比较财务报表中会计政策变更对以前期间净利润的追溯调整数0.00中国证监会认定的其他非经常性损益项目0.00所得税影响数0.00合计-237,821.883、净资产收益率及每股收益单位:元 币种:人民币报告期利润净资产收益率（%）每股收益全面摊薄加权平均全面摊薄加权平均主营业务利润27.4627.320.54520.5452营业利润1.391.390.02770.0277净利润0.190.190.00370.0037扣除非经常性损益后的净利润0.200.200.00410.00414、利润及利润分配表单位:元 币种:人民币项目合并母公司本期数上年同期数本期数上年同期数一、主营业务收入2,323,280,157.411,998,420,954.84721,218,324.58691,560,019.38减：主营业务成本1,902,182,203.611,628,237,403,02593,059,414.74561,590,657.09主营业务税金及附加5,737,215.855,366,137.324,373,150.004,779,821.91二、主营业务利润（亏损以“-”号填列）415,360,737.95364,817,414.50123,785,759.84125,189,540.38加：其他业务利润（亏损以“-”号填列）11,202,744.3610,811,858.813,032,086.848,393,698.16减:营业费用116,625,980.2252,366,981.6127,146,339.7525,952,554.34管理费用183,172,369.50173,172,458.3675,784,774.6085,846,459.73财务费用105,681,674.8273,911,521.3460,073,160.0247,576,473.95三、营业利润（亏损以“-”号填列）21,083,457.7776,178,312.00-36,186,427.69-25,792,249.48加：投资收益（损失以“-”号填列）-2,091,417.42-2,378,517.2441,549,753.5356,186,894.28补贴收入753,993.00236,116.20753,993.00187,523.20营业外收入558,234.611,159,734.4881,624.72181,912.29减：营业外支出1,725,850.076,188,836.22541,234.201,858,277.81四、利润总额（亏损总额以“-”号填列）18,578,417.8969,006,809.225,657,709.3628,905,802.48减：所得税9,551,419.1028,874,803.1327,506.7229,468.49减：少数股东损益9,786,810.094,006,044.93加：未确认投资损失(合并报表填列)3,611,605.82五、净利润（亏损以“-”号填列）2,851,794.5236,125,961.165,630,202.6428,876,333.99加：年初未分配利润-184,189,277.05-164,538,525.1836,422,587.1034,810,761.52其他转入六、可供分配的利润-181,337,482.53-128,412,564.0242,052,789.7463,687,095.51减：提取法定盈余公积提取法定公益金提取职工奖励及福利基金(合并报表填列)4,993,709.367,562,891.08提取储备基金提取企业发展基金利润归还投资七、可供股东分配的利润-186,331,191.89-135,975,455.1042,052,789.7463,687,095.51减：应付优先股股利提取任意盈余公积应付普通股股利35,081,825.6735,081,825.67转作股本的普通股股利八、未分配利润(未弥补亏损以“-”号填列)-186,331,191.89-171,057,280.7742,052,789.7428,605,269.84 详见《华北制药股份有限公司二 医药网新闻